Incruse Ellipta 62.5 ug/1

Incruse Ellipta 62.5 ug/1 is a powder inhaler containing umeclidinium, used for managing chronic obstructive pulmonary disease (COPD). This maintenance medication helps improve breathing by relaxing the airways.

Incruse Ellipta 62.5 ug/1 is primarily used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles around the airways, making it easier to breathe. This medication is not intended for immediate relief of sudden breathing problems but is designed for regular use to manage symptoms over time.

Common effects of Incruse Ellipta 62.5 ug/1 may include dry mouth, throat irritation, and cough. Some users might experience headaches or nasal congestion. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Incruse Ellipta 62.5 ug/1 should be used as directed by a healthcare provider. It is important to follow the prescribed dosage and administration instructions. The inhaler should be stored in a clean, dry place and kept out of reach of children. Users with known allergies to umeclidinium or any of the inactive ingredients should avoid using this medication.

Incruse Ellipta 62.5 ug/1 may interact with other medications, including beta-agonists, anticholinergics, and certain antibiotics. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect the central nervous system should be used with caution while using this medication.